$CBIS Reports Strong Customer Interest

COLORADO SPRINGS, Colo., March 26, 2015 /PRNewswire/ — Choosing to present its products to the world at this year’s Spannabis Fair, held March 20-22 in Barcelona, Spain, Cannabis Science, Inc. (CBIS) immediately began meeting with representatives of businesses and organizations interested in providing the products to their customers from across Spain.

“It was a huge success,” stated, Mr. Mario S. Lap, European President of Operations. “This is the initial exposure we want for the successful launch of our brand in Europe letting the world know about us and our product pipeline. We are very excited to be in a position to simultaneously release our products in several new consumer spaces enabling us to now take orders on a wholesale level.”

Over three days, Spannabis 2015 attracted an estimated 50,000 visitors from around the world – and it was a very busy event for Cannabis Science. While Mr. Lap was taking initial product orders and meeting with prospective customers, the company’s multilingual European operations team answered numerous questions about Cannabis Science and its products from private individuals and companies and organizations from across Europe, Asia and the Americas.

“Interest in the company and our products was tremendous,” said Mr. Lap. “I have met with a significant number of new prospective customers and a number of our targeted area representatives responsible for purchases for their respective Companies, all of whom are interested in our products in some form or another.”

Under current Spanish regulatory structures, attendees interested in the product consisted of three main types of clientele:

• Cannabis companies that provide growing solutions, lighting and seeds that are now emerging to play an important part in the medical cannabis sector.

• Membership-only Spanish cannabis social clubs. In 2013, nearly 170,000 Spaniards started consuming cannabis. Cannabis Science sees this as a large addressable market that can be educated about the benefits of medical cannabinoid formulations and medicines.

• Organizations run by patients and doctors seeking to provide quality cannabinoid-based medical products to patients across Spain.

Spanish media coverage: https://www.lamarihuana.com/spannabis-2015-reportaje-fotografico/

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions.  The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus:  CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement.  The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward-looking statements.  Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties.  These forward-looking statements may be impacted, either positively or negatively, by various factors.  Information concerning potential factors that could affect the company are detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.

Media Contacts:
VAN STONE PUBLICITY
Carrol Van Stone
carrol@vanstonepublicity.com
Tel: 304-671-0244
Cannabis Science, Inc.
Raymond C. Dabney
President & CEO, Co-Founder
info@cannabisscience.com
Tel: 1.888.889.0888
Chad S. Johnson, Esq.
Director, COO & General Counsel
info@cannabisscience.com
Tel: 1.888.889.0888